Abstracts Archive - Page 1524 of 2425 - ACR Meeting Abstracts

Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Mark C. Genovese¹, Patrick Durez², Roy Fleischmann³, Yoshiya Tanaka⁴, Daniel E. Furst⁵, Hisashi Yamanaka⁶, Igor Vasyutin⁷, Thangavel Kaviarasu⁸, Elena Korneva⁷, Dmitry Koloda⁷ and Tsutomu Takeuchi⁹, ¹Stanford University Medical Center, Palo Alto, CA, ²Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ³Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁷R-Pharm CJSC, Moscow, Russian Federation, ⁸Quintiles Inc, Mumbai, India, ⁹School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…
Abstract Number: 1599 • 2016 ACR/ARHP Annual Meeting
Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program
Peter C. Taylor¹, Grace C. Wright², Carol L. Gaich³, Amy M. DeLozier³, Stephanie de Bono³, Douglas E. Schlichting³, Terence Rooney³, Jiajun Liu³, Scott D. Beattie⁴ and Maxime Dougados⁵, ¹NDORMS, University of Oxford, Oxford, United Kingdom, ²NYU Langone Medical Center, New York, NM, ³Eli Lilly and Company, Indianapolis, IN, ⁴Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁵Dept of Rheumatology, Cochin Hospital, Paris, France
Background/Purpose: Baricitinib (bari), an oral Janus kinase (JAK) 1/JAK2 selective inhibitor, has demonstrated clinical efficacy with a satisfactory safety profile when administered once daily in…
Abstract Number: 1600 • 2016 ACR/ARHP Annual Meeting
Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib By RAPID3: An Analysis of Data from 6 Phase 3 Studies
Martin J Bergman¹, Yusuf Yazici², Ara Dikranian³, Jeffrey Bourret⁴, Chuanbo Zang⁵, Christopher F Mojcik⁶ and Eustratios Bananis⁵, ¹Drexel University College of Medicine, Philadelphia, PA, ²New York University Division of Rheumatology, New York, NY, ³San Diego Arthritis Medical Clinic, San Diego, CA, ⁴Pfizer, Inc., Collegeville, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The treatment target for RA is remission or low disease activity (LDA).…
Abstract Number: 1601 • 2016 ACR/ARHP Annual Meeting
Maintenance Treatment Using Abatacept with Dose Reduction after Achievement of Low Disease Activity in Patients with Rheumatoid Arthritis (MATADOR) – a Prospective, Multicentered, Single Arm Clinical Trial
Shinsuke Yasuda¹, Kazumasa Ohmura¹, Hiroshi Kanazawa², Takashi Kurita¹, Yujiro Kon³, Tomonori Ishii⁴, Satoshi Jodo⁵, Kazuhide Tanimura⁶, Michio Minami⁷, Tomomasa Izumiyama⁸, Takumi Matsumoto⁹, Yoshiharu Amasaki¹⁰, Yoko Suzuki¹¹, Hideki Kasahara¹², Naofumi Yamauchi¹³, Akito Tsutsumi³, Hiromitsu Takemori², Takao Koike¹⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Rheumatology, Aomori Prefectural Central Hospital, Aomori, Japan, ³Department of Internal Medicine, Takikawa Municipal Hospital, Takikawa, Japan, ⁴Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁵Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, Japan, ⁶Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, ⁷Department of Rheumatology and Orthopaedic Surgery, Hokkaido Orthopaedic Memorial Hospital, Sapporo, Japan, ⁸Higashisendai Rheumatic Disease Clinic, Sendai, Japan, ⁹Division of Rheumatology, Kin-ikyo Chuo Hospital, Sapporo, Japan, ¹⁰The Center for Rheumatic Diseases, Tonan Hospital, Sapporo, Japan, ¹¹Izumi Himawari Clinic, Sendai, Japan, ¹²Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ¹³Sapporo Kiyota Hospital, Sapporo, Japan, ¹⁴NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: Aim of this study was to evaluate the feasibility of maintenance therapy with reduced dose of abatacept (ABT) to 250mg/body after achieving low disease…
Abstract Number: 1602 • 2016 ACR/ARHP Annual Meeting
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
Janet Pope¹, Edward Keystone², Shahin Jamal³, Lisy Wang⁴, Lara Fallon⁵, John Woolcott⁵, Irina Lazariciu⁶ and Boulos Haraoui⁷, ¹Western University, London, ON, Canada, ²Mount Sinai Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Canada, Montreal, QC, Canada, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Open-label, long-term extension (LTE) studies enrolled tofacitinib-treated patients (pts) to evaluate safety and…
Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Laura Cappelli¹, J. Lynn Palmer² and Clifton Bingham III³, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²CORRONA Research Foundation, Phoenix, AZ, ³Johns Hopkins University, Baltimore, MD
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…
Abstract Number: 1604 • 2016 ACR/ARHP Annual Meeting
a First-in-Human Study of CR6086, a New Potent EP4 Prostanoid Receptor Antagonist, Demonstrates Good Safety and Tolerability at Therapeutically Relevant Exposures
Stefano Persiani¹, Carla Manzotti¹, Cristina Vitalini¹, Giampaolo Giacovelli², Federica Girolami¹, Massimo D'Amato¹, Gianfranco Caselli¹ and Lucio C. Rovati^2,3, ¹Rottapharm Biotech, Monza, Italy, ²Clinical Research Department, Rottapharm Biotech, Monza, Italy, ³University of Milano Bicocca, Milano, Italy
Background/Purpose: CR6086 is a potent and selective antagonist of the prostaglandin EP4 receptor. EP4 receptors have a role in T-cell differentiation and expansion, and thus…
Abstract Number: 1605 • 2016 ACR/ARHP Annual Meeting
Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older
Roy Fleischmann¹, Mark C. Genovese², Janet van Adelsberg³, Erin Mangan⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶ and TWJ Huizinga⁷, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab (150 or 200 mg every 2 weeks [q2w] subcutaneously) + MTX demonstrated efficacy vs placebo…
Abstract Number: 1606 • 2016 ACR/ARHP Annual Meeting
Metrotexate Treatment Inmunomodulate the Abnormal Cytokine Expression Present in NaïVe Rheumatoid Arthritis Patients
Jorge Monserrat Sanz¹, Ana Maria Gómez Lahoz¹, Maria Dolores Sosa Reina¹, Cristina Bohórquez Heras², Atusa Movasat², Ana Pérez Gómez², Lucía Ruiz Gutiérrez², Ana Sánchez Atrio², Eduardo Cuende Quintana², M José León², David Diaz³, Fernando Albarrán Hernández² and Melchor Alvarez-Mon^2,3, ¹Medicine and Medical Specialities, Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain, ²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ³Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
Background/Purpose: Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA) patients. Since the first reports of the efficacy of low-dose MTX in…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 1608 • 2016 ACR/ARHP Annual Meeting
Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis
Edward Keystone¹, Ronald F van Vollenhoven², Bethanie Wilkinson³, Lara Fallon⁴, Lie-Ju Hwang⁵, Douglass Chapman⁵, Ryan DeMasi⁵ and Eun Bong Lee⁶, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³Pfizer Inc, Groton, CT, ⁴Pfizer Canada, Montreal, QC, Canada, ⁵Pfizer Inc, New York, NY, ⁶Seoul National University, Seoul, Korea, Republic of
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Treatment guidelines recommend targeting remission or low disease activity (LDA), herein…
Abstract Number: 1609 • 2016 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials
Stephen Hall¹, Peter Nash², Maureen Rischmueller³, Zirke Wiid⁴, David Witcombe⁵, David Gruben⁶, Ryan DeMasi⁷ and Tatjana Lukic⁷, ¹Cabrini Medical Centre, Monash University, Melbourne, Australia, ²University of Queensland, Brisbane, Australia, ³The Queen Elizabeth Hospital, Adelaide, Australia, ⁴Pfizer Australia, Sydney, Australia, ⁵Pfizer Australia, Sydney, NSW, Australia, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc analysis of data from Phase 3 studies investigated the efficacy…
Abstract Number: 1610 • 2016 ACR/ARHP Annual Meeting
Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers
Marius Albulescu¹, Jim Bush², Firas Almazedi², Ethan Grant³, Alex Godwood¹, Robert Miday⁴, Krista Arbaugh⁴, Lisa H. Butler¹, Michele Gunsior⁴, Jing Li⁵ and David Howe¹, ¹MedImmune, Cambridge, United Kingdom, ²Covance Clinical Research Unit, Leeds, United Kingdom, ³Translational Medicine, MedImmune, Gaithersburg, MD, ⁴MedImmune, Gaithersburg, MD, ⁵MedImmune, Mountain View, CA
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production. Previous clinical programs with intact monoclonal antibodies against CD40L have been discontinued due to…
Abstract Number: 1611 • 2016 ACR/ARHP Annual Meeting
In Vitro Cellular Profiling of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti–IL-6 Receptor Monoclonal Antibody
Konstantia-Maria Chavele¹, Debbie Gardner², Matthew J Loza², Bidisha Dasgupta², Martin Sims¹, David Shealy², Juliet Reid¹ and Ravi Rao¹, ¹GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ²Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: IL-6 plays a central pathogenic role in rheumatoid arthritis (RA). IL-6 signals through a complex of transmembrane IL-6R or soluble IL-6R (sIL-6R) with gp130…
Abstract Number: 1612 • 2016 ACR/ARHP Annual Meeting
Abatacept Targets T Follicular Helper Cells in Patients with Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo², Maiko Yoshikawa², Yusuke Miyazaki², Ippei Miyagawa³, Shigeru Iwata⁴, Kazuhisa Nakano⁵, Kazuyoshi Saito^6,7 and Yoshiya Tanaka⁸, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, KItakyushu, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), T cells can differentiate into functionally distinct subsets, leading to the persistent inflammation and immune abnormality associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].